This is the protocol for a review and there is no abstract. The objectives are as follows:
To identify whether early, aggressive therapy of BCC infections is able to achieve eradication after initial acquisition or prevent or delay onset of chronic infection and whether this improves clinical outcome measures such as lung function, nutritional status, clinical scores and mortality.
To determine whether there is an effective strategy to eradicate chronic BCC infection in people with CF and whether this therapy alters clinical and microbiological outcomes.
To determine whether these therapies are linked to any adverse effects or cause an increase the isolates of other species in the lower respiratory tract.
To assess any evidence of superiority between different therapies or therapeutic regimens with respect to cost-effectiveness or clinical outcome.